GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

Launched by MASSACHUSETTS GENERAL HOSPITAL · Aug 18, 2023

Keywords

ClinConnect Summary

The GLUCOSE-MGH trial is researching how genetic differences affect how people respond to a medication called oral semaglutide, which is used to treat type 2 diabetes. The study involves participants taking this medication for 14 days and then undergoing tests after eating a specially prepared breakfast. By measuring various substances in the blood, the researchers hope to learn more about how genetics can influence the body's reaction to the medication and help improve our understanding of type 2 diabetes.

To be eligible for this study, participants should be between the ages of 18 and 50, and they must not be taking any other diabetes medications. They should also have blood sugar levels that are in the range of normal to pre-diabetes. If you choose to participate, you can expect to attend two visits where you'll eat a meal and have blood samples taken to monitor your body's response before and after taking the medication. It's an exciting opportunity to contribute to important research that could lead to better treatments for diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males or non-pregnant females
• • 2. Ages 18-50 (inclusive)
• • 3. Able/willing to give consent
• • 4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data)
• Exclusion Criteria:
• • 1. Currently taking medications or intending to take medications for diabetes
• • 2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones
• • 3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis
• • 4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
• • 5. Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation
• • 6. History of cirrhosis and/or aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal
• • 7. Dietary restrictions preventing consumption of a MMTT
• • 8. Women who are pregnant, nursing, or at risk of becoming pregnant
• • 9. Participation in other interventional studies during the current study